Immunotech Laboratories, Inc. announced the updates for the International Clinical Trials of the company's patented AIDS-HIV ‘IPF' Medicine(s). The company has negotiated with two of the biggest hospitals in Bulgaria (thus, European Union) to carry clinical trials of IPF-ITV-1 and ITV-2 as: At the Infectious Disease Hospital, Sofia, with Hospital Director Prof. Cherveniakova will carry out clinical trials of ITV-1 with 50 patients infected with HIV-AIDS in its most advanced stage. At the Military Hospital, Sofia, with Hospital Director Prof. General Stoyan Tonev will carry out clinical trials of ITV-2 with 50 patients ill with chronic hepatitis in its most advanced stage.

The clinical trials will be conducted parallel with protease inhibitor. The clinical trials in Bulgaria (Referred to as, EU) are scheduled to begin in March 2013 and end in August 2013, which will give Immunotech, the rights to receive approval for huge applications of the "IPF" Medicines.